Fluoroquinolone Safety in Pediatric Patients: A Prospective, Multicenter, Comparative Cohort Study in France

Abstract

The rates of PAEs and musculoskeletal PAEs were higher for the FQ group than the control group. This observation supports the American Academy of Pediatrics statement restricting off-label FQ use in pediatric patients to second-line treatment in a limited number of situations.

Antibiotic resistance of Streptococcus pneumoniae in children with acute otitis media treatment failure

“…This is similar to previous studies on AOM treatment failure that indicate 40 or 55% of S. pneumoniae isolates were multidrug-resistant [18,24]. Many authors have reported that a large proportion of AOM is caused by multidrugresistant S. pneumoniae strains [11,12,23].…”

Epidemiology, Antimicrobial Resistance and &beta;-lactamase Genotypic Features of Enteropathogenic <i>Escherichia coli</i> Isolated from Children with Diarrhea in Southern China

“…Resistance to cotrimoxazole and chloramphenicol were more than 50z; however, most strains were susceptible to cefoperazone/sulbactam and imipenem (96.6z and 100z, respectively). Although 81z of strains were susceptible to ciprofloxacin, the use of quinolones is limited in pediatric patients because of musculoskeletal antibiotic-associated potential adverse events (26). The rate of multiple-drug resistance (MDR) EPEC in our samples was 58.6z, lower than that in a previous report (16).…”

In vitro Antibacterial Activities of New Fluoroquinolones against Clinical Isolates of <i>Haemophilus influenzae</i> with Ciprofloxacin-Resistance-Associated Alterations in GyrA and ParC

“…The pediatric usages of fluoroquinolones have been restricted because there were some concerns such as risk of arthropathy for the use of quinolones in children. However, the recent reports say the safety profile of fluoroquinolones in children is not substantially different from that of adults, and these types of drugs in the treatment of otolaryngology infections in children were effective [32][33][34]. It might be possible that any extension of the indications of off-label use of fluoroquinolones in pediatric patients would be given after large clinical trials in children, although Sazawal et al [35] concluded in their report that quinolone should be continued as the second-line drugs to treat children, only after failure of an early treatment.…”